RE: Interview: Why & When !7 Jun 2023 09:12
For me, CART will be done later than I had hoped but i am now an eternal optimist. This part was more exciting for new investors for the future :-
It’s worth reminding investors that while the current focus is on the progression of HEMO-CAR-T, the company has a broad pipeline including the Chimeric Bait Receptor ‘CBR’ platform technology, designed to programme immune cells to eliminate viral infections by destroying the viruses that cause them. Sandler says this is “is poised to change the way we fight viral infections.”
He also lists the ‘horrible viruses’ the company is addressing including Ebola, Zika, SARS Covid 2, Marburg, Dengue and Chikungunya. The focus now though is addressing the FDA’s concerns and returning to the important catalyst of clinical trials.